CSP exam test(specialty pharmacy)With Correct Answers! LATEST UPDATE/100%PASS

CSP exam test(specialty pharmacy)With
Correct Answers! LATEST
UPDATE/100%PASS
Leave the first rating

Save




Terms in this set (50)


PDC = (# of unique days with supply /
PDC calculation
number of days in a period) x 100

Which medication is d. Xeljanz (tofacitinib)
a Jak inhibitor?
a. Humira
(adalimumab)
b. Orencia
(abatacept)
c. Actemra
(toclizumab)
d. Xeljanz
(tofacitinib)

,Which medication a. Actemra (toclizumab)
can elevate
cholesterol?
a. Actemra
(toclizumab)
b. Enbrel
(etanercept)
c. Simponi
(golimumab)
d. Kineret (anakinra)

Which shingles c. Shingrix
vaccine is safe to
administer with TNF
inhibitors?
a. Adacel
b. Zostavax
c. Shingrix
d. Varivax

Most biologics b. Taltz (ixekizumab)
increase the risk of
infections, which of
the following also
increases the risk of
neutropenia?
a. Rituxin (rituximab)
b. Taltz (ixekizumab)
c. Remicade
(infliximab)
d. Cimzia
(certolizumab
pegol)

,Which psoriasis b. Otezla (apremilast)
medication does
not require
screening for
tuberculosis?
a. Stelara
(ustekinumab)
b. Otezla
(apremilast)
c. Cocentyx
(seculinumab)
d. Humira
(adalimumab)

, What is the b. 160mg subcutaneously once, followed
standard starting by 80mg subcutaneously every 4 weeks
dose for Taltz
(ixekizumab) when
used to treat
psoriatic arthritis?
a. 160mg
subcutaneously
once, followed by
80mg
subcutaneously at
weeks 2, 4, 6, 8, 10
and 12; then 80mg
subcutaneously
every 4 weeks
b. 160mg
subcutaneously
once, followed by
80mg
subcutaneously
every 4 weeks
c. 160mg
subcutaneously
once, followed by
80mg
subcutaneously
every week for 4
weeks,
then 80mg every 4
weeks
d. 160mg
subcutaneously
once, followed by